Daclizumab: A Potential Asthma Therapy?

Author(s): Sabina A. Antoniu.

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 4 , Issue 3 , 2010

Become EABM
Become Reviewer

Abstract:

Airways inflammation in asthma is triggered and maintained by CD4+ (Th2) cells which are activated by IL-2 and stimulate the eosinophilic inflammation, IgE secretion and mucus hyperproduction. Current anti-inflammatory therapies include inhaled corticosteroids, and leukotriene modifiers but they are not universally effective. IL-2 pathway inhibition might represent a potent anti-inflammatory therapy in asthma given the cytokine early role in the asthma complex inflammatory cascade and daclizumab which is a IL-2R blocker currently used as an immunsupressor in organ transplantation might be a potential asthma therapy. This is a review on the pathogenic role of IL-2, on the therapeutic potential of daclizumab and on its related patents.

Keywords: CD25, subunit-IL-2 receptor, CD4+ activation, daclizumab, asthma

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 4
ISSUE: 3
Year: 2010
Page: [214 - 221]
Pages: 8
DOI: 10.2174/187221310793564254
Price: $58

Article Metrics

PDF: 4